2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

Which Primary Drivers Are Supporting the Continued Market Growth of theChoroidal Neovascularization Market?

The rising prevalence of age-related macular degeneration (AMD) is expected to drive the growth of the choroidal neovascularization (CNV) market. AMD is a leading cause of central vision loss in older adults, and it is primarily influenced by aging, lifestyle factors, genetics, and exposure to environmental risks. One of the most severe manifestations of AMD is wet AMD, which is associated with choroidal neovascularization (CNV), where abnormal blood vessels grow beneath the retina, causing vision deterioration. Treatments such as anti-VEGF therapy are crucial for managing CNV and slowing AMD progression. With the global aging population and the growing incidence of AMD, projections indicate that by 2040, there may be 300 million cases of AMD. As a result, the increasing prevalence of AMD is driving the growth of the CNV market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21142&type=smp

How Will the Growth Rate of theChoroidal Neovascularization Market Impact Industry Trends by 2034?

The choroidal neovascularization market has grown strongly, expected to expand from $3.37 billion in 2024 to $3.61 billion in 2025, with a CAGR of 8.1%. Key historical growth drivers include an increase in sedentary lifestyle diseases, rising cases of age-related macular degeneration, a growing incidence of retinal illnesses, an aging population, rising eye care costs, and expanding screening initiatives.

The choroidal neovascularization market is anticipated to see steady growth, reaching $5.64 billion by 2029 at a CAGR of 7.7%. Growth drivers include increasing patient awareness, wider adoption of optical coherence tomography angiography, a rising demand for minimally invasive procedures, favorable reimbursement policies, and an expanding elderly population. Key trends in the forecast period include the emergence of intravitreal anti-VEGF therapies, the development of new gene-based treatments, advancements in gene therapy approaches, the growing use of telemedicine, the introduction of combination therapies, and the evolution of personalized treatment strategies.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21142

How Are Consumer Market Innovations Shaping the Current and Future Landscape of theChoroidal Neovascularization Market?

Leading companies in the choroidal neovascularization market are working on developing advanced therapies, such as photodynamic therapy, to offer eye care professionals precise and efficient treatment options that enhance patient outcomes and treatment effectiveness. Photodynamic therapy (PDT) uses a photosensitizing agent activated by light to target and destroy abnormal or cancerous cells. For example, in February 2023, Bausch & Lomb, a healthcare company from Canada, and Modulight, a biomedical company from Finland, announced the FDA-approved ML6710i photodynamic laser. This therapy, in combination with Bausch + Lomb’s VISUDYNE therapy, is designed to treat choroidal neovascularization caused by age-related macular degeneration (AMD). The modern, mobile ophthalmic laser provides a targeted approach to treating abnormal blood vessels in the eye, helping prevent further disease progression and preserving vision.

Who Are the Key Market Players Influencing the Growth of the Corn and Choroidal Neovascularization Industry?

Major companies operating in the choroidal neovascularization market are Pfizer Inc., Roche Holding AG, AbbVie Inc., Bayer Aktiengesellschaft, Novartis AG, Teva Pharmaceutical Industries Limited, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Biogen Inc., Chugai Pharmaceutical Co. Ltd., Alcon Inc., Genentech Inc., Bausch + Lomb Incorporated, Samsung Bioepis Co. Ltd., Santen Pharmaceutical Co. Ltd., Apellis Pharmaceuticals Inc., Kodiak Sciences Inc., Xbrane Biopharma AB, Allergan Inc., Adverum Biotechnologies Inc., Clearside Biomedical Inc., Sylentis S.A.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/choroidal-neovascularization-global-market-report

Which Key Market Segments Comprise the Choroidal Neovascularization Market and Drive Its Revenue Growth?

The choroidal neovascularization market covered in this report is segmented –

1) By Treatment Type: Anti-Angiogenic Therapy, Laser Photocoagulation, Photodynamic Therapy, Verteporfin Sodium, Ranibizumab, Bevacizumab, Aflibercept, Pegaptanib Sodium

2) By Indication: Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME), Central Serous Chorioretinopathy (CSC), Polypoidal Choroidal Vasculopathy (PCV), Myopic Macular Degeneration (MMD), Other Indications

3) By Route Of Administration: Intravitreal, Subconjunctival, Periocular, Oral

4) By End User: Hospitals, Ophthalmology Clinics, Ambulatory Surgical Centers, Research Centers

Subsegments:

1) By Anti-Angiogenic Therapy (Anti-VEGF Therapy): Ranibizumab, Bevacizumab, Aflibercept, Pegaptanib Sodium

2) By Laser Photocoagulation: Thermal Laser Photocoagulation, MicroPulse Laser Therapy

3) By Photodynamic Therapy (PDT): Standard PDT, Low-Fluence PDT, Half-Dose PDT

4) By Verteporfin Sodium: Intravenous Administration, Combination Therapy With Anti-VEGF

5) By Ranibizumab: Monthly Dosing, As-Needed Dosing, Treat-and-Extend Regimen

6) By Bevacizumab: Off-Label Use, Compounded Intravitreal Injections

7) By Aflibercept: Fixed-Dosing Regimen, Treat-and-Extend Regimen

8) By Pegaptanib Sodium: Monotherapy, Combination Therapy

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=21142&type=smp

Which Regions Are Emerging as Leaders in the Choroidal Neovascularization Market?

North America was the largest region in the choroidal neovascularization market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the choroidal neovascularization market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Global Choroidal Neovascularization Market 2025, By The Business Research Company:

Autologous Cell Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/autologous-cell-therapy-global-market-report

Cell and Gene Therapy Manufacturing Services Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-manufacturing-services-global-market-report

Mycoplasma Testing Global Market Report 2025

https://thebusinessresearchcompany.com/report/mycoplasma-testing-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: